{"id":"1eac9ba8-5ba2-504b-9781-a7fe2c367cd6","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:oral-nattokinase-lowers-circulating-advanced-glycation-end-products","predicate":"reduces","statement":"A high-nattokinase diet inhibited the rise in circulating advanced glycation end products in streptozotocin-diabetic rats.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"540e47e7-889e-53b2-a8b1-565646813596","mechanism_event_label":"A high-nattokinase diet inhibited the rise in circulating advanced glycation end products in streptozotocin-diabetic rats.","subject":{"id":"6b03a125-209a-5060-8b35-ec9e0e54033c","slug":"nattokinase","display_name":"Nattokinase / subtilisin NAT","entity_type_key":"peptide"},"object":{"id":"ad930105-9afc-5bed-b8f0-66896efc7ea8","slug":"advanced-glycation-endproduct-formation","display_name":"Advanced glycation end-product formation","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"540e47e7-889e-53b2-a8b1-565646813596","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:oral-nattokinase-lowers-circulating-advanced-glycation-end-products-event","event_type":"observed_intervention","label":"A high-nattokinase diet inhibited the rise in circulating advanced glycation end products in streptozotocin-diabetic rats.","description":"Circulating AGEs and renal histopathology","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6b03a125-209a-5060-8b35-ec9e0e54033c","slug":"nattokinase","display_name":"Nattokinase / subtilisin NAT","entity_type_key":"peptide"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"ad930105-9afc-5bed-b8f0-66896efc7ea8","slug":"advanced-glycation-endproduct-formation","display_name":"Advanced glycation end-product formation","entity_type_key":"cellular_process"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"14 days","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Rat (streptozotocin-induced diabetes)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Diet containing 0.6 mg nattokinase per gram","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The low-dose diet at 0.2 mg/g did nothing, so this is dose-dependent. The authors state explicitly that it is unclear whether the effect is caused by intact nattokinase or by peptides derived from it during digestion, which is the same open question this whole chapter turns on.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Rat (streptozotocin-induced diabetes)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A high-nattokinase diet inhibited the rise in circulating advanced glycation end products in streptozotocin-diabetic rats.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Effect of nattokinase on the pathological conditions in streptozotocin induced diabetic rats. (2024) https://pubmed.ncbi.nlm.nih.gov/38586318/ DOI: 10.1016/j.heliyon.2024.e28835","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vivo, oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Circulating AGEs and renal histopathology","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ade981f6-1e24-5bcb-a5d3-f422fe0569ab","evidence_kind":"source_excerpt","locator":"Lines 1313-1313","start_line":1313,"end_line":1313,"excerpt":"A high-nattokinase diet inhibited the rise in circulating advanced glycation end products in streptozotocin-diabetic rats.","model_system":"Rat (streptozotocin-induced diabetes)","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}